Articles related to CHECKPOINT INHIBITORS

When immune checkpoint inhibitor therapy was started, detectable levels of acetaminophen in the plasma were linked to significantly poorer PFS and OS. The fact that poorer clinical outcomes were demonstrated to be unrelated to other prognostic variables, such as age, performance status, the quantity of past lines of therapy, and tumor kind, is noteworthy.

Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRASinhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led tolower rates of grade 3-4 treatment-related adverse events compared with beginningadministration of the treatments concurrently.

JAK inhibitors provide a relatively tolerable drug option for controlling symptoms, reducing splenomegaly, and improving quality of life, but often at the expense of worsening cytopenias and without halting disease progression or preventing leukemic transformation. In this article, the authors review FDA–approved JAK inhibitors as well as those in late-phase clinical trials, and provide a schema for choosing among the available options for patients with MF.

This phase III trial evaluated the PARP inhibitor fuzuloparib versus placebo as a maintenance treatment after second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. Two-hundred-fifty-two (252) patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). Twice daily oral fuzuloparib as maintenance therapy was superior to placebo in PFS improvement. Further, benefit was observed both in patients with germline BRCA 1/2 mutations and in those without mutations.

This paring of PARP inhibitor and immune checkpoint inhibitor may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib with the anti CTLA-4 antibody ipilimumab achieved a 6-month PFS rate of 59.6%, which was superior to the comparator — a clinically meaningful benchmark of 44%. The results were not the same when a PD-1 inhibitor (nivolumab) were used. That trial arm yielded a poorer 6-month PFS vs the benchmark.

Few classes of therapeutics have been specifically developed to combat migraine, despite its global impact on disability. However, after 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine.